First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients With Advanced/Metastatic Solid Tumors

This study is testing a new experimental medicine called EMB-01 to see how safe it is and how well it works for people with advanced or spreading solid tumor cancers, such as non-small-cell lung cancer. It is the first time this drug is being given to people, aiming to find new ways to treat cancers that have not responded to standard therapies.

You may be eligible if you have advanced cancer that has spread, specifically non-small-cell lung cancer with certain genetic markers called EGFR or cMet. You must have already tried standard treatments without success or been unable to tolerate them, and you must be willing to undergo genetic testing to confirm your eligibility.

If you join, you will receive the experimental medication EMB-01 under the close supervision of a medical team who will monitor your health and how the tumor responds. You will also have regular check-ups and imaging scans to track your progress and ensure your safety throughout the study.

The study is being conducted at medical centers in Boston, Massachusetts; Detroit, Michigan; and Canton, Ohio. The current status of this trial is unknown, so it is recommended to reach out to a site directly for the most current enrollment information.